High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients

被引:45
作者
Molnar, Miklos Z. [1 ,2 ]
Streja, Elani [1 ,3 ]
Kovesdy, Csaba P. [4 ,5 ]
Budoff, Matthew J. [6 ]
Nissenson, Allen R. [6 ,7 ]
Krishnan, Mahesh [7 ]
Anker, Stefan D. [8 ]
Norris, Keith C. [6 ]
Fonarow, Gregg C. [6 ]
Kalantar-Zadeh, Kamyar [1 ,6 ,9 ]
机构
[1] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Harold Simmons Ctr Chron Dis Res & Epidemiol, Torrance, CA 90509 USA
[2] Semmelweis Univ, Inst Pathophysiol, Budapest, Hungary
[3] Univ Calif Los Angeles, Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90024 USA
[4] Salem VA Med Ctr, Div Nephrol, Salem, VA USA
[5] Univ Virginia, Div Nephrol, Charlottesville, VA USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[7] DaVita Inc, Denver, CO USA
[8] Free Univ Berlin, Dept Appl Cachexia, D-1000 Berlin, Germany
[9] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA
基金
美国国家卫生研究院;
关键词
OUTCOME PREDICTABILITY; HEART-FAILURE; MUSCLE MASS; HEMODIALYSIS; SURVIVAL; MALNUTRITION; INFLAMMATION; ASSOCIATION; TIME; IRON;
D O I
10.3945/ajcn.111.014639
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 [营养与食品卫生学];
摘要
Background: It is not clear why cardiac or renal cachexia in chronic diseases is associated with poor cardiovascular outcomes. Platelet reactivity predisposes to thromboembolic events in the setting of atherosclerotic cardiovascular disease, which is often present in patients with end-stage renal disease (ESRD). Objectives: We hypothesized that ESRD patients with relative thrombocytosis (platelet count >300 x 10(3)/mu L) have a higher mortality rate and that this association may be related to malnutrition-inflammation cachexia syndrome (MICS). Design: We examined the associations of 3-mo-averaged platelet counts with markers of MICS and 6-y all-cause and cardiovascular mortality (2001-2007) in a cohort of 40,797 patients who were receiving maintenance hemodialysis. Results: The patients comprised 46% women and 34% African Americans, and 46% of the patients had diabetes. The 3-mo-averaged platelet count was 229 +/- 78 x 10(3)/mu L. In unadjusted and case-mix adjusted models, lower values of albumin, creatinine, protein intake, hemoglobin, and dialysis dose and a higher erythropoietin dose were associated with a higher platelet count. Compared with patients with a platelet count of between 150 and 200 x 10(3)/mu L (reference), the all-cause (and cardiovascular) mortality rate with platelet counts between 300 and <350, between 350 and <400, and >= 400 x 10(3)/mu L were 6% (and 7%), 17% (and 15%), and 24% (and 25%) higher (P < 0.05), respectively. The associations persisted after control for case-mix adjustment, but adjustment for MICS abolished them. Conclusions: Relative thrombocytosis is associated with a worse MICS profile, a lower dialysis dose, and higher all-cause and cardiovascular disease death risk in hemodialysis patients; and its all-cause and cardiovascular mortality predictability is accounted for by MICS. The role of platelet activation in cachexia-associated mortality warrants additional studies. Am J Clin Nutr 2011;94:945-54.
引用
收藏
页码:945 / 954
页数:10
相关论文
共 43 条
[1]
Aljaroudi Wael A, 2005, Curr Hematol Rep, V4, P397
[2]
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease [J].
Angiolillo, Dominick J. ;
Bernardo, Esther ;
Sabate, Manel ;
Jimenez-Quevedo, Pilar ;
Costa, Marco A. ;
Palazuelos, Jorge ;
Hernandez-Antolin, Rosana ;
Moreno, Raul ;
Escaned, Javier ;
Alfonso, Fernando ;
Banuelos, Camino ;
Guzman, Luis A. ;
Bass, Theodore A. ;
Macaya, Carlos ;
Fernandez-Ortiz, Antonio .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (16) :1541-1547
[3]
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study [J].
Anker, SD ;
Negassa, A ;
Coats, AJS ;
Afzal, R ;
Poole-Wilson, PA ;
Cohn, JN ;
Yusuf, S .
LANCET, 2003, 361 (9363) :1077-1083
[4]
Platelet nitric oxide synthesis in uremia and malnutrition: A role for L-arginine supplementation in vascular protection? [J].
Brunini, Tatiana M. C. ;
Mendes-Ribeiro, Antonio C. ;
Ellory, John C. ;
Mann, Giovanni E. .
CARDIOVASCULAR RESEARCH, 2007, 73 (02) :359-367
[5]
Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients [J].
Chan, Kevin E. ;
Lazarus, J. Michael ;
Thadhani, Ravi ;
Hakim, Raymond M. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (04) :872-881
[6]
Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey [J].
Coresh, J ;
Astor, BC ;
Greene, T ;
Eknoyan, G ;
Levey, AS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (01) :1-12
[7]
Effects of nutritional status on the L-arginine-nitric oxide pathway in platelets from hemodialysis patients [J].
da Silva, CD ;
Brunini, TMC ;
Reis, PF ;
Moss, MB ;
Santos, SFF ;
Roberts, NB ;
Ellory, JC ;
Mann, GE ;
Mendes-Ribeiro, AC .
KIDNEY INTERNATIONAL, 2005, 68 (05) :2173-2179
[8]
EFFECTS OF THE RECOMBINANT HEMATOPOIETIC GROWTH-FACTORS INTERLEUKIN-3, INTERLEUKIN-6, STEM-CELL FACTOR, AND LEUKEMIA INHIBITORY FACTOR ON THE MEGAKARYOCYTIC DIFFERENTIATION OF CD34+ CELLS [J].
DEBILI, N ;
MASSE, JM ;
KATZ, A ;
GUICHARD, J ;
BRETONGORIUS, J ;
VAINCHENKER, W .
BLOOD, 1993, 82 (01) :84-95
[9]
CLINICAL AND EXPERIMENTAL STUDY OF PLATELET FUNCTION IN CHRONIC RENAL-FAILURE [J].
EVANS, EP ;
BLOOM, AL ;
BRANCH, RA .
JOURNAL OF CLINICAL PATHOLOGY, 1972, 25 (09) :745-&
[10]
Fernandez-Real J M, 2001, BMC Med Genet, V2, P6, DOI 10.1186/1471-2350-2-6